“1. American Public Health Security and Innovation

R&D to strengthen and safeguard the health and quality of life of individuals, families, and communities is a top priority for the Trump Administration. COVID-19 has highlighted the extent to which public health threats and challenges can impact economic and national security. The Administration is committed to focusing on R&D initiatives that improve health while ensuring a retooled economy that optimizes innovation.

Diagnostic, Vaccine, and Therapeutic R&D: As has been demonstrated with COVID-19, the importance of detection, prevention, response, and control to protect all Americans against infectious diseases or other bio-threats is paramount and requires the coordinated effort of all relevant departments and agencies. Departments and agencies should continue to support R&D that will contribute to timely development of modernized devices and equipment, diagnostics, therapeutics, and vaccines within the medical countermeasures enterprise.

Infectious Disease Modeling, Prediction, and Forecasting: The United States must improve epidemiological modeling R&D, as well as use such models on a continuous basis rather than employing them only in times ofcrisis. Relevant departments and agencies should enhance their ability to predict future pandemics by continuing to advance data and forecasting science to inform a more streamlined, better coordinated, and continual whole-of-society approach to addressing future infectious disease outbreaks.

Biomedicine and Biotechnology: Departments and agencies should prioritize accelerated identification and selection of R&D investments including the rapid detection, containment, and treatment of infectious diseases. Topics include pharmaceutical and non-pharmaceutical interventions, personalized medicine, neuroscience, and opioids, and advancing other IotF areas such as AI and advanced manufacturing-technologies that have been critical in ensuring rapid R&D of vaccines and therapeutics for pathogens such as COVID-19.”